INVO FERTILITY, INC.
Last · —$0.59-0.05 (-7.81%)live · yahoo · 1h ago
Vol 174.3K ≈ 102.8K
MA10MA20MA50
Market cap$2.71M—
P/E · TTM0.0fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session
Issuer
Legal nameINVO FERTILITY, INC.
HQUnited States (US)
ListingUS IVF
ISINUS44984F8804
SectorHealthcare
IndustryHealthcare Products
SIC3841
CurrencyUSD
Entity registrysec:0001417926
CIK0001417926
Websitewww.invofertility.com
Employees41
| Revenue | $7.5M |
|---|---|
| Operating income | $-2.9M |
| Net income | $-7.1M |
| Free cash flow | $-3.0M |
| Operating margin | -38.2% |
| Net margin | -94.2% |
| Return on equity | -43.0% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
10-K · 2026-06-02
From latest 10-K · 2026-06-02
- Going Concern
- Capital Needs
- Secured Debt
- Clinic Acquisitions
- Wfi Settlement
- Material Weakness
- Single Manufacturer
- Fertility Regulation
Red flags
- The company reported an accumulated net loss of $91.4 million through December 31, 2025 and explicitly disclosed substantial doubt about its ability to continue as a going concern.
- Management does not expect current cash to fund operations and service debt for the next 12 months; failure to raise capital could force the company to curtail or discontinue operations.
- Secured creditors, including Decathlon, may seize and liquidate company assets following a debt default.
- The WFI dispute was settled for $6.0 million, with substantial payments extending through December 2026 and 25% of gross funding proceeds above $2.0 million in any six-month period allocated to accelerate settlement payments.
- Disclosure controls and internal control over financial reporting were not effective at December 31, 2025 because of limited segregation of duties and inadequate accounting resources; these were identified as material weaknesses.
- The company relies on a single third-party manufacturer for INVOcell production, creating concentrated supply and product-quality risk.
Press & signals
- GlobeNewswire
INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability
- GlobeNewswire
INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure
Documents
FormReporting forFiledFlags
Showing 5 of 104 filings